The use of lytic mycobacteriophages to treat tuberculosis under conditions of acquired resistance to anti-tuberculosis drugs is one of the most practical ways to improve the effectiveness of therapy and reduce the spread of this disease. We studied the efficacy of antimycobacterial action of mycobacteriophage D29 encapsulated into 400-nm liposomes in cell models of tuberculosis infection in vitro. The antimycobacterial action of lytic mycobacteriophage D29 used in free or liposome-encapsulated forms was demonstrated on cell models of intracellularly infected RAW264.7 macrophages and tuberculous granuloma formed by human blood mononuclear cells. The experiments demonstrated pronounced advantage of liposomal form of mycobacteriophage according to the criteria of their penetration into macrophages and lysis of Mycobacterium tuberculosis in culture.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10517-020-04887-6 | DOI Listing |
bioRxiv
October 2024
Department of Chemical and Materials Engineering, University of Alberta, Edmonton, Alberta, Canada.
The global tuberculosis (TB) epidemic affected 10 million people and caused 1.3 million deaths in 2022 alone. Multidrug-resistant TB is successfully treated in less than 60% of cases by long, expensive and aggressive treatments.
View Article and Find Full Text PDFJ Virol
October 2024
Microbiology and Molecular Biology Laboratory, Department of Biological Sciences, Indian Institute of Science Education and Research, Bhopal, India.
Emergence of antibiotic resistance in pathogenic () has elevated tuberculosis to a serious global threat, necessitating alternate solutions for its eradication. D29 mycobacteriophage can infect and kill several mycobacterial species including . It encodes an endolysin LysA to hydrolyze host bacteria peptidoglycan for progeny release.
View Article and Find Full Text PDFBMC Microbiol
September 2024
Department of Bioengineering, Indian Institute of Science, Bengaluru, India.
Tuberculosis (TB) remains a major global health concern, with drug-resistant strains posing a significant challenge to effective treatment. Bacteriophage (phage) therapy has emerged as a potential alternative to combat antibiotic resistance. In this study, we investigated the efficacy of widely used mycobacteriophages (D29, TM4, DS6A) against Mycobacterium tuberculosis (M.
View Article and Find Full Text PDFMol Microbiol
August 2024
Microbiology and Molecular Biology Laboratory, Department of Biological Sciences, Indian Institute of Science Education and Research (IISER), Bhopal, India.
Endolysins produced by bacteriophages hydrolyze host cell wall peptidoglycan to release newly assembled virions. D29 mycobacteriophage specifically infects mycobacteria including the pathogenic Mycobacterium tuberculosis. D29 encodes LysA endolysin, which hydrolyzes mycobacterial cell wall peptidoglycan.
View Article and Find Full Text PDFHeliyon
March 2024
Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Chongqing, China.
( is the pathogen of human tuberculosis (TB). Resistance to numerous stresses, including oxidative stress, is determinant for intracellular survival, and understanding associated mechanisms is crucial for developing new therapeutic strategies. Rv2617c has been associated with oxidative stress response when interacting with other proteins in ; however, its functional promiscuity and underlying molecular mechanisms remain elusive.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!